aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Clarametyx Biosciences Inc., founded as a preclinical stage biotechnology company, is dedicated to developing a platform of immune-enabling biologic therapies and vaccines aimed at combating life-threatening infections. Their core mission is to innovate in the field of infectious disease treatment by targeting and dismantling bacterial biofilms, which are often resistant to conventional antibiotics. Clarametyx's primary product pipeline includes CMTX-101, an immune-enabling antibody therapy currently showing promising early-phase safety results.
The company has attracted significant attention and investment, securing $33 million in Series A financing to advance its anti-biofilm biologics. Notable affiliated individuals include renowned experts who have joined their strategic and scientific advisory boards to bolster their research and development efforts. Clarametyx's achievements in early-phase clinical trials and their growing team of specialists underscore their potential impact on the treatment of serious bacterial infections, positioning them as a promising player in the biotech industry.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Vaccines, Biologics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Clarametyx Biosciences founded?
Clarametyx Biosciences was founded in 2020.
Where is Clarametyx Biosciences’s headquarters located?
Clarametyx Biosciences’s headquarters is located in Columbus, OH, US.
When was Clarametyx Biosciences’s last funding round?
Clarametyx Biosciences’s most recent funding round was for $33M (USD) in January 2024.
How many employees does Clarametyx Biosciences have?
Clarametyx Biosciences has 14 employees as of Feb 5, 2024.
How much has Clarametyx Biosciences raised to-date?
As of July 05, 2023, Clarametyx Biosciences has raised a total of $59.2M (USD) since Jan 5, 2024.
Add Comparison
Total Raised to Date
$59.2M
USD
Last Update Jan 5, 2024
Last Deal Details
$33M
USD
Jan 5, 2024
Series A
Total Employees Over Time
14
As of Feb 2024
Clarametyx Biosciences Address
1275 Kinnear Rd
Columbus,
Ohio
43212
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts